Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Autologous ACTR T Cells with Rituximab in CD20+ B-Cell Malignancies
NCT02315118Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Dec 2014
- Primary completion
- Dec 2017
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ACTR087 in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), sponsored by National University Hospital. Primary endpoints: Performance status assessed by age-dependent Performance Scores, Toxicity criteria and 2 more. Status: unknown.
02
Drugs
ACTR087
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02315118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315118.